A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma

Trial Identifier: D822GC00001
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: July 2028
Study Completion Date: July 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations